These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 23934332)
21. Promoter methylation and polymorphisms of the MGMT gene in glioblastomas: a population-based study. Zawlik I; Vaccarella S; Kita D; Mittelbronn M; Franceschi S; Ohgaki H Neuroepidemiology; 2009; 32(1):21-9. PubMed ID: 18997474 [TBL] [Abstract][Full Text] [Related]
22. ¹⁸F-fluorodeoxyglucose and ¹¹C-methionine positron emission tomography in relation to methyl-guanine methyltransferase promoter methylation in high-grade gliomas. Choi H; Bang JI; Cheon GJ; Kim YH; Park CK; Park SH; Kang KW; Chung JK; Kim EE; Lee DS Nucl Med Commun; 2015 Mar; 36(3):211-8. PubMed ID: 25340951 [TBL] [Abstract][Full Text] [Related]
23. Comparative Molecular Life History of Spontaneous Canine and Human Gliomas. Amin SB; Anderson KJ; Boudreau CE; Martinez-Ledesma E; Kocakavuk E; Johnson KC; Barthel FP; Varn FS; Kassab C; Ling X; Kim H; Barter M; Lau CC; Ngan CY; Chapman M; Koehler JW; Long JP; Miller AD; Miller CR; Porter BF; Rissi DR; Mazcko C; LeBlanc AK; Dickinson PJ; Packer RA; Taylor AR; Rossmeisl JH; Woolard KD; Heimberger AB; Levine JM; Verhaak RGW Cancer Cell; 2020 Feb; 37(2):243-257.e7. PubMed ID: 32049048 [TBL] [Abstract][Full Text] [Related]
24. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. Wick W; Hartmann C; Engel C; Stoffels M; Felsberg J; Stockhammer F; Sabel MC; Koeppen S; Ketter R; Meyermann R; Rapp M; Meisner C; Kortmann RD; Pietsch T; Wiestler OD; Ernemann U; Bamberg M; Reifenberger G; von Deimling A; Weller M J Clin Oncol; 2009 Dec; 27(35):5874-80. PubMed ID: 19901110 [TBL] [Abstract][Full Text] [Related]
25. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Paz MF; Yaya-Tur R; Rojas-Marcos I; Reynes G; Pollan M; Aguirre-Cruz L; García-Lopez JL; Piquer J; Safont MJ; Balaña C; Sanchez-Cespedes M; García-Villanueva M; Arribas L; Esteller M Clin Cancer Res; 2004 Aug; 10(15):4933-8. PubMed ID: 15297393 [TBL] [Abstract][Full Text] [Related]
26. A case of multicentric gliomas in both supra- and infratentorial regions with different histology: a case report. Inoue A; Ohnishi T; Kohno S; Mizuno Y; Kitazawa R; Nakamura Y; Ohue S World J Surg Oncol; 2016 May; 14(1):152. PubMed ID: 27230073 [TBL] [Abstract][Full Text] [Related]
27. [Detection of O6-methylguanine-DNA methyltransferase promoter methylation in chemotherapy for glioma]. Zheng CQ; Ji SP; Gong F; Li AM; Tai JL; Zhang YP Ai Zheng; 2009 Jun; 28(6):575-80. PubMed ID: 19635193 [TBL] [Abstract][Full Text] [Related]
28. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients. Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864 [TBL] [Abstract][Full Text] [Related]
30. Single-copy gain of chromosome 1q is a negative prognostic marker in pediatric nonependymal, nonpilocytic gliomas. Miwa T; Hirose Y; Sasaki H; Ezaki T; Yoshida K; Kawase T Neurosurgery; 2011 Jan; 68(1):206-12. PubMed ID: 21099717 [TBL] [Abstract][Full Text] [Related]
31. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. Weller M; Felsberg J; Hartmann C; Berger H; Steinbach JP; Schramm J; Westphal M; Schackert G; Simon M; Tonn JC; Heese O; Krex D; Nikkhah G; Pietsch T; Wiestler O; Reifenberger G; von Deimling A; Loeffler M J Clin Oncol; 2009 Dec; 27(34):5743-50. PubMed ID: 19805672 [TBL] [Abstract][Full Text] [Related]
32. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas. Leeper HE; Caron AA; Decker PA; Jenkins RB; Lachance DH; Giannini C Oncotarget; 2015 Oct; 6(30):30295-305. PubMed ID: 26210286 [TBL] [Abstract][Full Text] [Related]
33. Expression of mutated isocitrate dehydrogenase-1 in gliomas is associated with p53 and EGFR expression. Birner P; Toumangelova-Uzeir K; Natchev S; Guentchev M Folia Neuropathol; 2011; 49(2):88-93. PubMed ID: 21845536 [TBL] [Abstract][Full Text] [Related]
34. Immunohistochemical profiles of IDH1, MGMT and P53: practical significance for prognostication of patients with diffuse gliomas. Ogura R; Tsukamoto Y; Natsumeda M; Isogawa M; Aoki H; Kobayashi T; Yoshida S; Okamoto K; Takahashi H; Fujii Y; Kakita A Neuropathology; 2015 Aug; 35(4):324-35. PubMed ID: 25950388 [TBL] [Abstract][Full Text] [Related]
35. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Wiestler B; Capper D; Holland-Letz T; Korshunov A; von Deimling A; Pfister SM; Platten M; Weller M; Wick W Acta Neuropathol; 2013 Sep; 126(3):443-51. PubMed ID: 23904111 [TBL] [Abstract][Full Text] [Related]
36. BRAF V600E-mutated diffuse glioma in an adult patient: a case report and review. Suzuki Y; Takahashi-Fujigasaki J; Akasaki Y; Matsushima S; Mori R; Karagiozov K; Joki T; Ikeuchi S; Ikegami M; Manome Y; Murayama Y Brain Tumor Pathol; 2016 Jan; 33(1):40-9. PubMed ID: 26445861 [TBL] [Abstract][Full Text] [Related]
37. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Wick W; Meisner C; Hentschel B; Platten M; Schilling A; Wiestler B; Sabel MC; Koeppen S; Ketter R; Weiler M; Tabatabai G; von Deimling A; Gramatzki D; Westphal M; Schackert G; Loeffler M; Simon M; Reifenberger G; Weller M Neurology; 2013 Oct; 81(17):1515-22. PubMed ID: 24068788 [TBL] [Abstract][Full Text] [Related]